Biotech · Private company
Exegenesis Bio
Track this companyFree. Adds Exegenesis Bio to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- Aflibercept (2.0 mg)Phase 1 · Neovascular Age-Related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- EXG102-031Phase 1 · Neovascular (Wet) Age-related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)PHASE1 · ACTIVE_NOT_RECRUITING · started Sep 10, 2024ClinicalTrials.gov NCT06817343 · fetched Nov 12, 2026
- A Study of EXG102-031 in Patients With wAMD (Everest)PHASE1 · COMPLETED · started Jul 24, 2023ClinicalTrials.gov NCT05903794 · fetched Nov 12, 2026